比索洛尔联合参麦注射液治疗冠心病心力衰竭的长期疗效研究

目的 探究比索洛尔联合参麦注射液治疗冠心病心力衰竭的长期疗效.方法 选取2012年3月至2015年3月接受治疗的冠心病心力衰竭患者150例,随机分为研究组和对照组,每组75例.其中,对照组采用常规药物进行治疗,研究组在对照组基础上加以比索洛尔联合参麦注射液进行治疗.于2个疗程治疗后,比较2组患者治疗有效率、心脏超声指标水平(LVEF、LVESV和LVEDV)、炎性因子水平及不良反应等,以评价比索洛尔联合参麦注射液在治疗冠心病心力衰竭中的价值.结果 通过治疗,研究组仅6例无效病例,治疗总有效率为92.00%,明显高于对照组(x2=4.485,P=0.034).治疗后,2组患者炎性因子水平均有明显的改善,IL-6、IL-8浓度与治疗前相比均有明显降低,且研究组降低幅度更为明显(P<0.05).通过治疗也明显改善了患者的心脏超声指标水平,研究组和对照组LVEF、LVESV和LVEDV水平较治疗前相比均有明显变化,且研究组各项指标优于对照组,差异有统计学意义(P<0.05).治疗期间,研究组共3例患者出现不良反应,其不良反应发生率为4.00%,对照组共10例患者出现不良反应,不良反应发生率为13.33%,2组比较差异有统计学意义(x2=4.127,P=0.042).结论 比索洛尔联合参麦注射液治疗冠心病心力衰竭具有更好的临床疗效,可有效改善患者的临床症状,提高患者的心功能,具有较好的临床推广价值.

Analysis for the long-term effects of bisoprolol combined with Shenmai injection on coronary heart disease with heart failure

Objective To observe the long-term effects of bisoprolol combined with Shenmai injection on coronary heart disease with heart failure .Methods One hundred and fifty patients with coronary heart disease complicated by heart failure who were treated in our hospital from March 2012 to March 2015 were randomly divided into research group and control group,with 75 patients in each group .The patients in control group were treated by conventional therapy , however, the patients in research group ,on the basis of control group , were treated by bisoprolol combined with Shenmai injection , with a treatment course of one month for both groups .Then the left ventricular ejection fraction ( LVEF) ,left ventricular end systolic volume (LVESV) and left ventricular end diastolic volume (LVEDV) were detected by ultrasonic cardiogram .The therapeutic effects, inflammatory factors levels and side effects were observed and compared between two groups to evaluate the application value of bisoprolol combined with Shenmai injection in treatment of coronary heart disease complicated by heart failure .Results The total effective rate in research group was 92.00%,which was significantly higher than that in control group (x2 =4.485, P <0.05).After treatment, the serum levels of IL-6 and IL-8 were significantly decreased in both groups ( P <0.05), moreover, the decrease extent in research group was more obvious than that in control group ( P <0.05).Moreover after treatment, the levels of LVEF, LVESV and LVEDV were obviously improved in both groups , furthermore, which in research group were superior to those in control group ( P <0.05).During treatment,only 3 patients in research group had adverse reactions, with incidence rate of side effects being 4.00%, however, 10 patients in control group had adverse reactions ,with incidence rate of side effects being 13 .33%, there was a significant difference between two groups (x2 =4.127, P <0.05).Conclusion The bisoprolol combined with Shenmai injection has better clinical efficacy in treatment of coronary heart disease complicated by heart failure ,which can significantly improve patient ' s clinical symptoms and enhance patient's cardiac function,thus,which is of great clinical application value .